Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

Study Identifier
P16-570
CT.gov Identifier
NCT03341871
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Hepatitis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    0 - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients with chronic hepatitis C virus infection and administering glecaprevir plus pibrentasvir.
    Exclusion Criteria:
    * Patients previously treated with glecaprevir plus pibrentasvir.

    Protocol Summary

    This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.

    Study Locations

    Location
    Status
    Location
    Abbvie Japan /ID# 161985
    Tokyo, Japan, 108-6302
    Status
    Not applicable